Overview

Study Of GW679769 In Major Depressive Disorder

Status:
Completed
Trial end date:
2006-09-01
Target enrollment:
Participant gender:
Summary
This is a placebo-controlled, fixed dose study that will evaluate the efficacy and safety of GW679769 in subjects with major depressive disorder.
Phase:
Phase 2
Details
Lead Sponsor:
GlaxoSmithKline
Treatments:
Casopitant